疏肝理脾片对干扰素联合利巴韦林治疗慢性丙型肝炎疗效的影响  

Shugan Lipi tablet in combination with interferon-alpha and ribavirin in the treatment of chronic hepatitis C

作　　者：伍玉南[1] 孙克伟[1] 彭建平[1] 陈斌[1] 黄裕红[1] 

机构地区：[1]湖南中医药大学第一附属医院传染科,湖南长沙410007

出　　处：《中西医结合肝病杂志》2009年第2期76-77,123,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的：评价疏肝理脾片对干扰素联合利巴韦林治疗慢性丙型肝炎疗效的影响。方法：43例慢性丙型肝炎患者随机分为治疗组和对照组,治疗组25例,治以疏肝理脾片,8片/次,口服,3次/d;重组人IFNα-2b（赛诺金）,5MU,肌注,隔日1次;利巴韦林800-1200mg/d,口服,联合治疗48周。对照组18例,予重组人IFNα-1b（赛诺金）,5MU,肌注,隔日1次;利巴韦林800-1200mg/d,口服,治疗48周。动态观察、比较治疗组与对照组的临床疗效及副作用。结果：治疗组与对照组比较,血清ALT及肝纤维化指标恢复水平均优于对照组（P〈0.05）,不良反应发生率低于对照组（P〈0.05）,患者耐受性更好。结论：疏肝理脾片在护肝降酶、减轻不良反应、抗肝纤维化方面对干扰素联合利巴韦林治疗慢性丙型肝炎患者具有良好的影响。Objective： To evaluate the efficiency and safety of Shugan Lipi tablet in combination with interferon-alpha and ribavirin in the treatment of chronic hepatitis C. Methods： Forty-three cases with chronic hepatitis C randomly divided into 2 groups： 25 patients was treatment group, 18 patients was control group. In treatment group, Shugan Lipi tablet was given orally, 8 tablets per time, 3 times daily, interferon-alphal b was given intramuscularly, 5 MU per time, every other day, ribavirin was given orally, 800 - 1200mg daily. In controll group, interferon-alphalb was given intramuscularly, 5MU per time, every other day, ribavirin was given orally, 800 - 1200mg daily. The courses of 2 groups were 48 weeks. Results： More recovery of serum ALT and hepatofibrosis index （HA, PC Ⅲ, C-Ⅳ, LN）, less adverse reactions and more tolerant were observed in treatment group than that in control group. Conclusion： Shugan Lipi tablet can effectively improve the liver function, side effects and hepatofibrosis index on the antiviral treatment of interferon alpha and ribavirin in chronic hepatitis C.

关 键 词：肝炎 丙型 疏肝理脾片 干扰素 

分 类 号：R512.63[医药卫生—内科学] R286.87[医药卫生—临床医学]